GLP-1 Medication Costs in 2026 (Complete Guide)

The number one question people ask about GLP-1 medications is not about side effects or efficacy — it is about cost. And for good reason. At full list price, these medications can cost over $16,000 per year. But the pricing landscape has shifted dramatically in 2025 and 2026, creating more affordable pathways than ever before.

This guide covers every FDA-approved GLP-1 medication on the market, what each one actually costs through different channels, and practical strategies to reduce your out-of-pocket expense.

GLP-1 Medication List Prices: The Full Picture

Let us start with the sticker prices. These are the wholesale acquisition costs (WAC) that manufacturers set for each medication. Almost no one pays these prices, but they serve as the baseline for insurance negotiations and pharmacy pricing.

Injectable GLP-1 Medications

Medication	Manufacturer	FDA Indication	Monthly List Price
Wegovy (semaglutide 2.4 mg)	Novo Nordisk	Weight management	$1,349/month
Ozempic (semaglutide up to 2 mg)	Novo Nordisk	Type 2 diabetes	$1,028/month
Zepbound (tirzepatide)	Eli Lilly	Weight management	$1,086/month
Mounjaro (tirzepatide)	Eli Lilly	Type 2 diabetes	$1,023/month

Oral GLP-1 Medications

Medication	Manufacturer	FDA Indication	Monthly List Price
Rybelsus (oral semaglutide 14 mg)	Novo Nordisk	Type 2 diabetes	$1,028/month
Oral Wegovy (oral semaglutide)	Novo Nordisk	Weight management	$149-$299/month (self-pay direct)

At list price, a year of Wegovy costs approximately $16,188 and a year of Zepbound costs approximately $13,032. These numbers explain why cost is the single biggest barrier to GLP-1 access — and why every pricing development in this space matters.

What You Actually Pay: Insurance Coverage

The gap between list price and what patients actually pay is enormous for those with insurance coverage.

Commercial Insurance (Employer-Sponsored and Marketplace Plans)

According to GoodRx data, patients with insurance coverage for GLP-1 medications pay an average of $331 per month after coverage kicks in. With manufacturer copay savings cards, many patients pay as little as $25 to $50 per month.

What determines your coverage:

Formulary status: Check whether your plan's drug formulary includes Wegovy, Zepbound, Ozempic, or Mounjaro. Many plans cover at least one product from each class.
Prior authorization: Nearly all plans require prior authorization for GLP-1 weight loss medications. Your doctor will need to document BMI (30+ or 27+ with comorbidities), failed lifestyle interventions, and relevant health conditions.
Step therapy: Some plans require you to try a lower-cost medication first (like Contrave or phentermine) before approving a GLP-1.
Quantity limits: Plans may limit the supply to 30 days at a time and require regular follow-up visits.

Coverage trends in 2026:

The percentage of commercial plans covering at least one GLP-1 for weight management has increased significantly from 2023 to 2026
Large employers are increasingly adding GLP-1 coverage after cost-benefit analyses showed reduced spending on obesity-related conditions like diabetes, heart disease, and joint replacements
Some plans have added coverage specifically for Wegovy's cardiovascular indication following the SELECT trial results

Medicare Coverage (2026 Updates)

Medicare's relationship with GLP-1 medications for weight loss has been complicated, but 2026 brings major changes.

Current law: Medicare is statutorily prohibited from covering drugs prescribed solely for weight loss. This exclusion has been in place since the program's creation.

What changed in 2025-2026:

In April 2025, the Trump administration rejected a Biden-era proposal to reinterpret Medicare rules to allow broader GLP-1 weight loss coverage
However, CMS launched the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model — a demonstration program that provides a pathway to coverage

BALANCE Model details:

Launches April 2026 as a voluntary model for Medicare Advantage and Part D plans
Covers GLP-1 medications for beneficiaries with obesity (BMI 30+) and qualifying comorbidities
Medicare pricing set at approximately $245/month for injectable GLP-1 medications
Beneficiary copay capped at $50/month
Includes mandatory lifestyle intervention and counseling components
A separate Part D demonstration may provide broader access by July 2026

What this means for Medicare patients:

If you are on Medicare and have obesity with conditions like type 2 diabetes, cardiovascular disease, or sleep apnea, you may gain access to GLP-1 medications at $50/month starting mid-2026. Check with your Medicare plan to see if they are participating in the BALANCE model.

The Treat and Reduce Obesity Act:

This bipartisan bill would permanently remove Medicare's exclusion of weight loss medications. It has been introduced in multiple Congressional sessions and was marked up by the House Committee on Ways and Means in June 2024, but has not yet been enacted into law as of March 2026.

Medicaid Coverage

Medicaid coverage for GLP-1 weight loss medications varies significantly by state:

A growing number of states cover GLP-1 medications for obesity through their Medicaid programs
Most state Medicaid programs cover Ozempic and Mounjaro when prescribed for type 2 diabetes
Coverage for weight management specifically (Wegovy, Zepbound) is less common but expanding
Prior authorization requirements are strict, and quantity limits are common

Contact your state Medicaid program or check your plan's formulary for specific coverage details.

Manufacturer Self-Pay and Savings Programs

Both Novo Nordisk and Eli Lilly have introduced direct-to-consumer pricing that bypasses the traditional insurance model entirely.

Novo Nordisk Programs (Wegovy, Ozempic, Rybelsus)

Self-pay pricing (launched late 2025, expanded in 2026):

Standard price: $349/month for Wegovy injection and Ozempic
Introductory offer: $199/month for the first 2 months for new self-pay patients (available through March 31, 2026)
Oral Wegovy: $149-$299/month depending on dose
Available through NovoCare.com and participating pharmacies
No insurance required — this is a cash-pay option

Savings cards for insured patients:

Eligible patients with commercial insurance can pay as little as $25/month
Available through the Novo Nordisk savings card program
Does not apply to government insurance (Medicare, Medicaid, Tricare)

Costco partnership:

Wegovy and Ozempic available at $499/month for cash-paying Costco members
No Costco membership required for pharmacy purchases in most states

Eli Lilly Programs (Zepbound, Mounjaro)

LillyDirect pricing:

Eli Lilly offers Zepbound and Mounjaro through their LillyDirect platform with competitive self-pay pricing
Available via home delivery through LillyDirect partner pharmacies

Walmart partnership:

Walmart offers Zepbound at comparable cash pricing to Costco's arrangement with Novo Nordisk
Available at Walmart pharmacy locations nationwide

Savings cards:

Eligible commercially insured patients may pay as low as $25/month for Mounjaro or Zepbound
Maximum savings limits apply

Compounded Semaglutide: The Budget Option (With Caveats)

Compounded semaglutide has been the most affordable way to access GLP-1 medication, but its future is uncertain.

What Is Compounded Semaglutide?

When the FDA determines a brand-name drug is in shortage, compounding pharmacies are legally permitted to produce copies. Semaglutide was on the FDA drug shortage list for an extended period, which opened the door to compounded versions at dramatically lower prices.

Current Pricing (2026)

Provider	Form	Monthly Cost
Hims	Injectable compounded semaglutide	$175/month
Hims	Oral compounded semaglutide	$79-$175/month
GobyMeds	Injectable (3-month starter)	$119/month
Various telehealth	Injectable compounded	$150-$300/month

The Regulatory Situation

The availability of compounded semaglutide is one of the most contentious issues in healthcare right now:

The FDA has moved to remove semaglutide from the drug shortage list multiple times, which would eliminate the legal basis for compounding
Novo Nordisk has pursued legal action against compounding pharmacies producing semaglutide
Several federal court cases have produced conflicting rulings — some allowing compounding to continue, others issuing injunctions
Hims & Hers announced in March 2026 plans to phase out compounded semaglutide and transition patients to FDA-approved products, though they have not set a firm end date

What to Know Before Choosing Compounded

Not FDA-approved: Compounded medications do not undergo the same testing and quality controls as FDA-approved products
Quality varies: Sourced from state-licensed pharmacies, but potency and sterility standards vary
Availability risk: May become unavailable if courts rule against compounding or FDA shortage status changes
No long-term guarantee: Unlike brand-name products with established supply chains, compounded access could end abruptly

If you are currently using compounded semaglutide, have a backup plan. Discuss transition options with your provider, including the Novo Nordisk self-pay program at $349/month.

Telehealth GLP-1 Programs: Full Cost Breakdown

Telehealth platforms have made GLP-1 access significantly more convenient. Here is what the major providers charge.

Hims

Compounded semaglutide injection: $175/month (all-inclusive — medication, provider visits, shipping)
Compounded oral semaglutide: Starting at $79/month
FDA-approved medications: Available at insurance or self-pay pricing; Hims facilitates prescriptions for Wegovy and Ozempic
Includes: Provider consultation, ongoing monitoring, messaging support
Plans for $49 compounded semaglutide pill have been announced, though Novo Nordisk has threatened legal action

Ro (Roman)

Program cost: $494-$644 for initial evaluation and medication supply
Includes: Provider consultation, prescription management, metabolic testing
Medication cost: Varies depending on whether using compounded or brand-name products
Body Program: Comprehensive weight loss program with GLP-1 access and coaching

Found

Monthly membership: Varies by medication and program tier
Includes: Board-certified provider, prescription management, health coaching, community support
Accepts insurance: Found works with many commercial insurance plans to reduce medication costs

Other Telehealth Options

PlushCare, Sesame, Done: Various telehealth platforms now offer GLP-1 consultations and prescriptions
Cost structure: Typically a consultation fee ($50-$200) plus medication cost (insurance, self-pay, or compounded)

The Hidden Costs of GLP-1 Therapy

The medication itself is the biggest expense, but it is not the only one. Understanding the full cost picture helps you budget realistically and avoid surprises.

Doctor Visits and Monitoring

GLP-1 prescriptions require ongoing medical supervision:

Initial consultation: $150-$350 (specialist) or $50-$150 (primary care copay with insurance). Telehealth consultations are often cheaper at $50-$150.
Follow-up visits: Every 1-3 months, depending on your provider. Budget $25-$75 per visit with insurance.
Lab work: Blood tests to monitor kidney function, liver function, blood sugar, and lipids. Typically $50-$200 per panel without insurance, or $10-$50 copay with insurance. Most providers order labs every 3-6 months.

Nutrition and Lifestyle Support

Many patients benefit from complementary support:

Registered dietitian: $100-$200 per session without insurance (many insurance plans cover nutrition counseling for obesity). A dietitian can help you maximize nutrition quality when your appetite is significantly reduced — this becomes important because you are eating less, so every calorie needs to count.
Protein supplements: $20-$50/month. Adequate protein intake (0.7-1.0 grams per pound of goal body weight) is critical to preserve muscle mass during rapid weight loss. Many patients need supplements to hit their protein targets with reduced appetite.
Gym membership or personal training: $30-$150/month. Resistance training 2-3 times per week is strongly recommended to prevent muscle loss, which can account for up to 40% of weight lost without exercise.

Anti-Nausea and Supportive Medications

During dose escalation, you may need:

Ondansetron (Zofran): $5-$30/month with insurance for anti-nausea support
Fiber supplements: $10-$20/month if constipation becomes an issue
Electrolyte supplements: $10-$25/month to manage hydration during GI side effects

Total Monthly Budget Estimates

Scenario	Medication	Add-on Costs	Total Monthly
Best case (insured)	$25-$50	$50-$100	$75-$150
Self-pay (Novo program)	$349	$50-$100	$400-$450
Telehealth compounded	$79-$175	$50-$100	$130-$275
No insurance, list price	$1,023-$1,349	$50-$100	$1,073-$1,449

Strategies to Reduce Your GLP-1 Costs

Regardless of your insurance status, there are practical steps you can take to lower what you pay.

Strategy 1: Check Your Insurance Formulary First

Before exploring other options, verify what your plan covers:

Call the number on your insurance card and ask about GLP-1 coverage
Check the plan's online formulary for Wegovy, Zepbound, Ozempic, and Mounjaro
Ask about prior authorization requirements and what documentation your doctor needs to submit
Find out if step therapy is required

Strategy 2: Use Manufacturer Savings Cards

If you have commercial insurance:

Novo Nordisk Savings Card: Can reduce Wegovy or Ozempic copays to $25/month
Lilly Savings Card: Similar reductions for Mounjaro and Zepbound
Limitations: Not available for government insurance (Medicare, Medicaid, VA, Tricare)

Strategy 3: Consider the Self-Pay Programs

If you do not have insurance coverage for GLP-1 medications:

Novo Nordisk: $349/month ($199 introductory) for Wegovy/Ozempic
Costco/Walmart: $499/month cash pricing
Compare these to your insurance copay — sometimes self-pay is cheaper than using insurance with a high deductible

Strategy 4: Ask About the Diabetes Indication

If your doctor identifies prediabetes, metabolic syndrome, or type 2 diabetes:

Ozempic and Mounjaro may be covered under your plan's diabetes formulary even when Wegovy and Zepbound are denied for weight loss
A1C of 5.7% or above qualifies as prediabetes
This is a legitimate clinical approach, not a workaround — these medications treat metabolic conditions

Strategy 5: Appeal Insurance Denials

If your claim is denied:

Ask your doctor to submit a letter of medical necessity
Include documentation of BMI, comorbidities, failed lifestyle interventions, and relevant clinical guidelines
Reference the American Medical Association's recognition of obesity as a disease
For Wegovy specifically, cite the SELECT trial cardiovascular benefit if you have cardiovascular risk factors
Most plans have a formal appeals process — use it

Strategy 6: Explore Patient Assistance Programs

For patients who meet income qualifications:

Novo Nordisk Patient Assistance Program (PAP): May provide Wegovy or Ozempic at no cost for qualifying uninsured patients
Lilly Cares: Similar assistance for Mounjaro and Zepbound
Eligibility: Generally requires household income below 400% of the federal poverty level and no insurance coverage for the medication

Strategy 7: Consider Oral Formulations

Oral Wegovy: $149-$299/month through Novo Nordisk's direct channel
Significantly cheaper than injectable Wegovy at list price
Eliminates pen and needle costs
May be a good starting point for patients new to GLP-1 therapy

Price Comparison: All Options at a Glance

Here is a summary table comparing every major way to access GLP-1 medications in 2026:

Access Method	Monthly Cost	Pros	Cons
Brand-name with insurance	$25-$331	Lowest cost if covered; FDA-approved	Prior auth required; may be denied
Novo Nordisk self-pay	$199-$349	No insurance needed; FDA-approved	Higher than compounded options
Costco/Walmart cash	$499	Simple; no insurance needed	Higher than manufacturer self-pay
Oral Wegovy	$149-$299	No injections; affordable	Daily dosing; newer formulation
Hims compounded injectable	$175	Affordable; includes provider care	Not FDA-approved; may lose availability
Hims compounded oral	$79-$175	Lowest cost; no needles	Regulatory uncertainty; not FDA-approved
Ro program	$494-$644	Comprehensive care; metabolic testing	Higher upfront cost
Medicare (BALANCE model)	~$50 copay	Very affordable	Limited to qualifying beneficiaries; starts mid-2026
Patient assistance	$0	Free medication	Income-qualified; application process
Full list price	$1,023-$1,349	Immediate access	Unsustainable for most patients

International Price Comparison: Why GLP-1s Cost More in the US

Understanding global pricing provides context for why US prices are what they are — and where they might be headed.

What Other Countries Pay

According to a 2025 Peterson-KFF Health System Tracker analysis, GLP-1 medication prices in the United States are significantly higher than in other developed nations:

United States: Wegovy at $1,349/month list price (before discounts)
United Kingdom: Wegovy available at approximately $250-$350/month through the NHS
Germany: Comparable GLP-1 pricing at $300-$500/month
Canada: Ozempic available at approximately $250-$350 CAD/month
Denmark (Novo Nordisk's home country): Significantly lower pricing than the US

The price differential exists because the US does not directly negotiate drug prices at the federal level the way most other countries do. However, this is changing. The Inflation Reduction Act of 2022 gave Medicare the power to negotiate prices for certain high-cost drugs, and GLP-1 medications are candidates for future negotiation cycles.

Medical Tourism Considerations

Some patients have explored purchasing GLP-1 medications from international pharmacies:

Important: Importing prescription medications from other countries is generally illegal under US law (with limited personal-use exceptions)
Quality concerns: Medications purchased from unverified international sources may be counterfeit, improperly stored, or contaminated
Better alternatives exist: With Novo Nordisk's $349/month self-pay program and compounded options under $200/month, the cost savings from international purchasing are no longer as significant — and the risks are not worth it

The Cost-Benefit Analysis: Is It Worth the Money?

This is the question behind the question. With GLP-1 medications costing $4,000 to $16,000+ per year at various price points, is the investment justified?

The Health Economics Perspective

Research consistently shows that effective obesity treatment reduces downstream healthcare costs:

Type 2 diabetes prevention: The STEP 1 trial showed that semaglutide helped 84.1% of participants with prediabetes revert to normal blood sugar levels. Preventing diabetes avoids an estimated $16,752 per year in diabetes-related medical costs.
Cardiovascular events: The SELECT trial showed Wegovy reduced heart attacks, strokes, and cardiovascular deaths by 20%. A single heart attack costs an average of $100,000+ in acute treatment and long-term care.
Joint replacements: Weight loss of 10-15% can delay or eliminate the need for knee and hip replacements ($30,000-$50,000 per surgery).
Sleep apnea resolution: Many patients can stop CPAP therapy after significant weight loss, saving $200-$500/year in equipment costs plus improving quality of life.
Reduced medication burden: Patients who lose significant weight often reduce or eliminate medications for blood pressure, cholesterol, and blood sugar — savings of $50-$300/month.

The ICER Analysis (2025)

The Institute for Clinical and Economic Review (ICER) published a comprehensive cost-effectiveness analysis of GLP-1 medications for obesity in 2025. Their findings suggested that at list prices, GLP-1 medications exceeded traditional cost-effectiveness thresholds. However, at the lower self-pay prices ($349/month for semaglutide) and considering the full range of health benefits (cardiovascular, metabolic, quality of life), the cost-effectiveness improves substantially.

A Personal Cost-Benefit Framework

When evaluating whether GLP-1 therapy is worth the cost for your situation, consider:

What is obesity costing you now? Add up current medications, medical visits, lost productivity, and reduced quality of life.
What conditions might you prevent? If you have prediabetes, hypertension, or sleep apnea, effective weight loss can reverse these conditions.
What is your time horizon? The health benefits compound over years, making the long-term value greater than the short-term cost.
Can you sustain the expense? A medication you can afford for 2+ years is better than one you can only afford for 6 months.

The Future of GLP-1 Pricing

Several developments suggest prices will continue to come down:

Novo Nordisk Price Cuts (2027)

In February 2026, Novo Nordisk announced plans to slash Ozempic and Wegovy list prices by up to 50% starting in 2027. This would bring Wegovy's list price below $700/month — still expensive, but a major reduction from $1,349.

Generic and Biosimilar Competition

Semaglutide patents will eventually expire, opening the door to generic competition
Biosimilar manufacturers are already preparing applications
When biosimilars enter the market, prices could drop by 30-80% based on historical patterns with other biologic drugs

Expanding Insurance Mandates

Several states are considering or have passed laws requiring insurance coverage of FDA-approved obesity medications
The federal Treat and Reduce Obesity Act would remove Medicare's weight loss drug exclusion
As coverage mandates expand, market competition should drive negotiated prices lower

New Competitors Entering the Market

Multiple pharmaceutical companies are developing next-generation GLP-1 and multi-receptor agonists
Amgen's MariTide, Viking Therapeutics' VK2735, and other candidates in late-stage trials could create pricing pressure
More competition typically leads to lower prices and better savings programs

Frequently Asked Questions

What is the cheapest way to get semaglutide right now?

The lowest-cost option in March 2026 is compounded oral semaglutide through telehealth platforms like Hims, starting at approximately $79/month. However, compounded products are not FDA-approved and face regulatory uncertainty. The cheapest FDA-approved option is Novo Nordisk's introductory self-pay pricing of $199/month for the first two months of Wegovy or Ozempic (through March 31, 2026), followed by $349/month standard self-pay pricing.

Does insurance typically cover GLP-1 for weight loss or only for diabetes?

Coverage has expanded significantly, but it depends on your specific plan. Most large commercial insurers now cover at least one GLP-1 for weight management with prior authorization. However, some plans still only cover GLP-1 medications under the diabetes indication (Ozempic, Mounjaro) and exclude the weight management versions (Wegovy, Zepbound). Check your plan's formulary and call your insurer's pharmacy benefits line for the most accurate information about your coverage.

Are the cheaper compounded versions just as effective as brand-name?

Compounded semaglutide contains the same active molecule as Ozempic and Wegovy. However, compounded products are not subject to the same FDA manufacturing oversight, and there can be variation in potency, sterility, and stability. When sourced from a reputable, state-licensed 503B compounding pharmacy, the medication should perform similarly. But there have been FDA warnings about substandard compounded products, so choosing a legitimate provider matters.

Will Medicare cover my GLP-1 medication in 2026?

It depends on your situation. Medicare currently does not cover GLP-1 drugs prescribed solely for weight loss. However, if you have type 2 diabetes, Medicare Part D will cover Ozempic or Mounjaro as diabetes medications. For weight loss specifically, the new BALANCE demonstration model launching in April 2026 will cover GLP-1 medications for Medicare beneficiaries with obesity and qualifying comorbidities at a $50/month copay — but your Medicare plan must be participating in the model.

How much do GLP-1 side effect management costs add up?

Beyond the medication itself, budget for potential ancillary costs: anti-nausea medication ($5-$30/month if needed during dose escalation), additional protein supplements to prevent muscle loss ($20-$50/month), regular lab work for monitoring ($50-$200 per visit depending on insurance), and follow-up provider visits ($25-$75 copay every 1-3 months). For most patients, these add $50-$150/month on top of the medication cost during the first few months, then decrease as side effects stabilize.

Final Takeaway

GLP-1 medications are more accessible and affordable in 2026 than at any point since they first came to market. The gap between the $1,349 list price and what patients actually pay is wider than ever, thanks to manufacturer self-pay programs, expanding insurance coverage, and telehealth options.

Your best path to affordability depends on your insurance status. If you have commercial coverage, start with your insurance formulary and manufacturer savings cards. If you are uninsured or your plan does not cover GLP-1 medications, the Novo Nordisk self-pay program at $349/month (or $199 introductory) is the most reliable FDA-approved option. Telehealth compounded options are cheaper but come with regulatory uncertainty.

The bottom line: do not let the list price scare you away from asking your doctor about GLP-1 therapy. There are real, sustainable ways to access these medications at a fraction of the sticker price.

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any medication.

Affiliate disclosure: The GLP-1 Daily may earn a commission from links in this article. This does not affect our editorial independence or the accuracy of our content.

Quick Answer